Immunologic and pharmacologic studies in allotransplant

描述(由申请人提供)：我的目标是开发一个移植临床研究计划，重点是移植免疫学和移植药理学/药物基因组学，并为这一领域的下一代临床研究人员做准备。提出了三个项目，这些项目加起来大约需要25%的努力。项目1和2有联邦资助，项目3将部分依赖于通过这笔赠款获得的资金。项目1：异体移植后的次要组织相容疫苗接种。(1R21 CA 101337-01，Quick Trial，PI，Koen van Besien)项目2：白花丹调节：优化，动力学，基因组学(1R21 CA115097-01，Quick Trial，PI，Koen van Besien)项目3：NKT细胞生物学和移植环境中的功能。这三个项目解决了移植过程中互补的临床问题，并且没有重叠。每个项目都有翻译和临床部分，所有项目都最大限度地利用了芝加哥大学目前的研究基础设施和经验。它们为学员提供了设计、实施和解释临床及相关研究的绝佳机会。因此，这些项目非常适合培养下一代研究人员，他们将需要整合临床和实验室研究的能力。我的指导工作需要大约25%的努力。他们将与该议定书的具体目标并行，并将集中在临床研究、药理学/药物基因组学实验室研究和免疫学实验室研究的职位上。几名初级教员已经在接受指导。他们包括两名临床调查人员和一名药理学家。分别列出了K23、K08或双PI R21的平面图。我期待着由我自己和另一位拥有不同专业知识的资深教职员工为这些调查人员提供双重指导。在整个拨款过程中，我将通过奖学金、住院医生和医学生计划寻找新的潜在研究人员，在那里我一直非常积极地从事教学和指导工作。

DESCRIPTION (provided by applicant): My objective is to develop a clinical research program in transplantation that focuses on transplant immunology and transplant pharmacology/pharmacogenomics, and that prepares the next generation of clinical investigators in this area. Three projects are proposed, which together will require approximately 25% effort. Project 1 and 2 have federal funding project 3 will partially depend on funding obtained by this grant. Project 1: Minor Histocompatibility Vaccination After Allo-Transplant. (1R21 CA 101337-01, Quick trial, PI, Koen van Besien) Project 2: Busulfan conditioning: optimization, kinetics, genomics (1R21 CA115097-01, Quick trial, PI, Koen van Besien) Project 3: NKT cell biology and functions in the transplant setting. The three projects address complementary clinical questions in transplant and are not overlapping. Each have translational as well as clinical components and all projects maximally utilize the current research infrastructure and experience at University of Chicago. They provide excellent opportunities for mentees to design, conduct and interpret clinical and correlative studies. These projects are therefore well suited to prepare the next generation of researchers who will require the ability to integrate clinical and laboratory research. My mentoring efforts require approximately 25% effort. They will parallel the specific aims of this protocol and will center on positions for clinical research, lab research in pharmacology/pharmacogenomics and lab research in immunology. Several junior faculty are already being mentored. They include two clinical investigators and one pharmacologist. Plans for K23, K08 or dual PI R21 are outlined for each. I anticipate dual mentorship by myself and by another senior faculty with different expertise for each of these investigators. Throughout the course of the grant I will identify new potential investigators through the fellowship, residency and medical student program, where I have been very active in teaching and mentoring.